NCT05378633Recruiting
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life. Therapy options for multiple brain metastases may vary and range from stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), chemotherapy, immunotherapy to palliative best supportive care. Especially the efficacy and toxicity of SRS compared to WBRT in patients with extensive brain metastases (\>4) is not yet clear but of incremental relevance in this seriously ill cohort with a limited life span. These health-impaired patients might especially profit from a less toxic treatment that is also time sparing with 1 or few sessions in SRS versus 10 sessions in WBRT. On the other hand, no compromises in efficacy want to be done.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- First submitted
- 24 Jan 2022
- Start date
- 24 Feb 2022
- Primary completion date
- 24 Feb 2027
- Lead sponsor
- University Hospital Heidelberg
- Diseases
- Lung cancer
- NCT number
- NCT05378633
What you commit to
- Study type: Interventional
- Planned participants: 190
- From 24 Feb 2022 to the primary completion date, 24 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to tolerate irradiation consistent with the protocol
- Previous radiotherapy of the brain
- Patients who have not yet recovered from acute high-grade toxicities of prior therapies
Other illness
- Small-cell lung cancer (SCLC) or lymphoma as primary malignant illness
- leptomeningeal disease
- MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)
Other
- Refusal of the patients to take part in the study
- \>15 suspect intracranial lesions, taking into consideration all available MRI series
- Pregnant or lactating women
- Participation in another competing clinical study or observation period of competing trials, respectively
Who the study is looking for
- histologically confirmed malignant illness
- 4-15 suspect intracranial lesions, taking into consideration all available MRI series
- age ≥ 18 years of age
- For women with childbearing potential, (and men) adequate contraception.
- Ability of subject to understand character and individual consequences of the clinical trial
- Written informed consent (must be available before enrolment in the trial)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Heidelberg, Radiation Oncology Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.